190 related articles for article (PubMed ID: 35834737)
21. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
22. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
Strand MA; Eukel H; Burck S
Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
[TBL] [Abstract][Full Text] [Related]
23. Improving Community Pharmacist-Delivered Care for Patients With Psychiatric Disorders Filling an Opioid Prescription.
Werremeyer A; Frenzel O; Strand MA; Eukel H; Skoy E; Steig J
Psychiatr Serv; 2022 Nov; 73(11):1294-1297. PubMed ID: 35502518
[TBL] [Abstract][Full Text] [Related]
24. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
25. Impact of a statewide community pharmacy approach to opioid harm reduction.
Sexton SM; Marciniak MW; Gatton O; Shelton P
J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
[TBL] [Abstract][Full Text] [Related]
26. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
Xu J; Mukherjee S
Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
[TBL] [Abstract][Full Text] [Related]
27. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
Rao D; Ford JH; Shiyanbola OO
Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
[TBL] [Abstract][Full Text] [Related]
28. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
29. Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?
Wunderlich JR; Engelberg RS; Tofighi B; Schwartz MD
J Gen Intern Med; 2022 Aug; 37(11):2621-2623. PubMed ID: 35581455
[No Abstract] [Full Text] [Related]
30. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
[TBL] [Abstract][Full Text] [Related]
31. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
32. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
33. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
Roberts AW; Carpenter DM; Smith A; Look KA
Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C.
Meyerson BE; Agley JD; Jayawardene W; Eldridge LA; Arora P; Smith C; Vadiei N; Kennedy A; Moehling T;
Res Social Adm Pharm; 2020 May; 16(5):699-709. PubMed ID: 31611071
[TBL] [Abstract][Full Text] [Related]
35. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
[TBL] [Abstract][Full Text] [Related]
36. Impact of Implementing Screening and Interventions to Target Prevention of Opioid Misuse and Accidental Overdose in the Inpatient Setting.
Bjornson S; Grindeland CJ; Werremeyer AB
J Pharm Pract; 2024 Apr; 37(2):442-447. PubMed ID: 36472932
[No Abstract] [Full Text] [Related]
37. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
38. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
Eldridge LA; Meyerson BE; Agley J
J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
[TBL] [Abstract][Full Text] [Related]
39. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
[TBL] [Abstract][Full Text] [Related]
40. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]